Skip to main content
. 2020 Feb 3;15(2):e0227719. doi: 10.1371/journal.pone.0227719

Fig 3.

Fig 3

Proportion of participants who seroconverted to at least one or all of the three vaccine strains at 1 month post-vaccination (A), and proportion of participants with seroprotection to at least 1 or all three of the vaccine strains at 1 month post-vaccination (B).